We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

GLOBAL NICOTINE REPLACEMENT THERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global Nicotine Replacement Therapy Market, By Product Type (Inhalers, Gum, Transdermal Patches, Sublingual Tablets, Lozenges. Others), By Distribution Channel (Online, Offline)), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

  • Published In : Dec 2023
  • Code : CMI6521
  • Pages :132
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Market News

Global Nicotine Replacement Therapy Market- Recent Developments

Product and technology Launch

  • In September 2022, 22nd Century Group, a leading agricultural biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technologies, launched VLN, a low-nicotine cigarette in Colorado, U.S.
  • In May 2022, Innokin Technology, a leading vape brand & manufacturer, launched a lineup of vaporizers with water-based vaping technology with water-based juice, AQ30. Water-based vaping delivers smoother vapor and faster satisfaction than traditional vaping systems and reduces the dehydrating qualities of vapor.
  • In August 2022, MOK, the leading brand from Shenzhen IVPS Technology, specializing in the research and development, production and sales of e-cigarettes, launched its new SOLUS 2 series at a special global product launch event in Jakarta, Indonesia. SOLUS 2 Series, an upgraded version of the SOLUS series of Vaping Devices.

Business Development Activities by the Market Players

  • In November 2022, Philip Morris International Inc., a U.S.-based multinational tobacco company, announced the launch of its latest heat-not-burn tobacco heating system, BONDS by IQOS with its accompanying specially designed tobacco sticks, BLENDS. A new product from IQOS, the world's No. 1 tobacco heating system. BONDS by IQOS offers adults who would otherwise continue to smoke access to a compact, low maintenance and hassle-free to use smoke-free offer—validated by science—as a better alternative to cigarettes—to accelerate the achievement of a smoke-free future.
  • In September 2022, Qnovia, Inc. (Qnovia), a pharmaceutical company developing inhaled therapeutics with an initial focus on nicotine replacement therapy (NRT) and cardiopulmonary diseases, announced that it had raised US$ 17 million in Series A funding. The financing was led by Blue Ledge Capital and included DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures, investment firms.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.